medigraphic.com

2003, Number 2

<< Back Next >>

Rev Fac Med UNAM 2003; 46 (2)

Detection of cervical cancer and HPV

Castellanos MMR

Language: Spanish
References: 27
Page: 63-66
PDF size: 39.66 Kb.


ABSTRACT

The impact of uterine cervix cancer in the world is devastating. It is the second highest cause of death in women in the whole world and the primary cause of female death in developing countries. The Human Papilloma Virus (HPV) has been found in 93% of all cases of invasive cancer, making infection by this virus and their precursory lesions the most important risk factor. In the United States of America, the incidence of cervix uteri cancer has been reduced dramatically following the implementation of the Papanicolaou test, reducing incidence by approximately 75%. Data from a number of Scandinavian studies show a great reduction in incidence and mortality after prevention programs have been initiated. Studies of cases and controls have found that the risk of developing invasive surgical cancer is 3 to 10 times greater in women who have not been examined. Since the Papanicolaou test is a routine procedure, patients with abnormal results should be given additional tests (colposcopy and biopsy). At present, a number of studies describe the possibility for using HPV typing to help in stratifying women into follow-up and treatment groups.


REFERENCES

  1. Muñoz N, Bosch FX, Cáncer del Cerviz y virus del papiloma humano: evidencia epidemiológica y perspectivas para su prevención. Sal Púb Méx 1997; 39: 388-396.

  2. Greenlee RT, Hill-Harmon MB, Murria T. Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001; 50: 7-33.

  3. Bosch FX, Mnos MM, Muñoz N, Shrman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J. Natl Cancer Inst 1995; 87: 796-802.

  4. Lazcano Ponce E, Nájera P, Alonso P, Buiatti E, Hernández M. Programa de Detección Oportuna de Cáncer Cervical en México. I Diagnóstico Situacional. Rev Inst Nal Cancerol (Mex) 1996; 42(3): 123-140.

  5. Pisani P, Parkin DM, Muñoz N, Ferlay J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1995; 61: 312-315.

  6. International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risk of chemical to humans. Human Papillomaviruses. Lyon IARC 1995; vol. 64.

  7. Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJLM, Walboomers JMM. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994; 69: 114-119.

  8. Muñoz N, Bosch FX, De Sanjosé S, Vergara A. Del Moral A, Muñoz MT et al. Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993; 2: 423-431.

  9. Aristizabal, N Cuello C, Correa P: The impact of vaginal cytology on cervical cancer risks in Cali, Colombia. Int J cancer 1984; 34(1): 5-9.

  10. Brisson J, Morin C, Fortier M, et al.; Risk factors for cervical intraepithelial neoplasia: differences between low and high-grade lesions. Am J Epidemiol 1994; 140(8): 700-710.

  11. Hernández-Avila M, Lazcano –Ponce EC, Berumen-Campos J, Human papilloma virus 16-18 infection and cervical cancer in México. A case-control study. Arch Med Res 1999; 28: 265-271.

  12. Torroella-Kouri M, Morsberger D, Carrillo A. et al. HPV prevalence among Mexican women with neoplastic and normal cervixes. Gynecol Oncol 1998; 70(1): 115-120.

  13. Frías-Mendivil M, Mohar A, Solorza-Luna G, et al. Virus del papiloma humano asociado a lesiones tempranas del cuello uterino Rev Inst Nal Cancerol (Mex) 1999; 45(2): 119-120.

  14. O‘Leary TJ et al. Journal scan: PAPNET-Assisted Rescreening of Cervical Smears Cost and Accuracy Compared with a 100% Manual Re-screening Strategy. Journal of the American Medical Association 1998; 279: 235-237.

  15. Laara E, Day NE, Hakama M: Trends in mortality from cervical cancer in the Nordic countries: association with organized screening programmes. Lancet 1, 1987; (8544): 1247-1247.

  16. Herrero R, Brinton LA, Reeves WC, et al: Screening for cervical cancer in Latin America: a case-control study. International Journal of Epidemiology 1992; 21(6): 1050-1056.

  17. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Madow P et al. Human papillomavirus testing in primary cervical screening. Lancet 1995; 345: 1533-1536.

  18. Janicek Mike E, Averette Herdy E. Prevención y diagnóstico del Cáncer de Cuello. CA Cancer J Clin 2001; 51: 92-114.

  19. Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996; 88: 1361-1368.

  20. Nevins JR. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424-429.

  21. 12ª Reunión Anual de la Asociación Española de Patología Cervical y Colposcopia conjunta con el “HGVP Clinical Workshop” Barcelona, Boletín No. 11 Febrero 2001.

  22. Kailash U, Hedau S, Gopalkrishna V, Katiyar S, Das BC. A simple ´paper smear´method for dry collection, transport and storage of cervical cytological specimens for rapid screening of HPV infection by PCR. J Med Microbiol 2002; 51(7): 606-10

  23. Adams KL. Confronting Cervical Cancer. Screening is the key to stopping this killer. AWHOMM Lifelines 2002; 6(3): 216-22.

  24. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Jaspars LH, Voorhorst FJ, Verheijen RH, Meijer CJ. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 2002; 55(6): 435-9.

  25. Dzuba IG, Diaz EY, Allen B, Leonard YF, Lazcano Ponce EC, Shah KV, Bishai D, Lorincz A, Ferris D, Turnbull B, Hernández Avila M, Salmeron J. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 2002; 11(3): 265-75.

  26. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287(18): 2372-81.

  27. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, Hernández P, Salmeron J, Hernández M. Epidemiology of HVP infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91(3): 412-20.




2020     |     www.medigraphic.com